Skip to content
Beractant
Survanta (beractant) is an unknown pharmaceutical. Beractant was first approved as Survanta on 1991-07-01. It is used to treat newborn respiratory distress syndrome in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
hereditary congenital and neonatal diseases and abnormalitiesD009358
Trade Name
FDA
EMA
Survanta
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Beractant
Tradename
Proper name
Company
Number
Date
Products
SurvantaberactantAbbVieN-20032 RX1991-07-01
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
survantaBiologic Licensing Application2020-10-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
newborn respiratory distress syndrome—D012127P22
Agency Specific
FDA
EMA
Expiration
Code
beractant, Survanta, AbbVie Inc.
2098-07-02Orphan excl.
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
27 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Allergic conjunctivitisD003233EFO_0007141H10.44—234—8
Allergic rhinitisD065631J30.91——1—2
HypersensitivityD006967EFO_0003785T78.40———1—1
CoughD003371HP_0012735R05———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Allergic rhinitis perennialD012221EFO_1001417J30.892—3——5
PruritusD011537HP_0000989L291—1——2
DermatitisD003872HP_0011123L30.9——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Allergic rhinitis seasonalD006255EFO_0003956J3014———4
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—4————4
UrticariaD014581EFO_0005531L501————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBERACTANT
INN—
Description
Beractant, also known by the trade name of Survanta, is a modified bovine pulmonary surfactant containing bovine lung extract (phospholipids, neutral lipids, fatty acids, and bovine surfactant proteins), to which synthetic DPPC, tripalmitin and palmitic acid are added. The composition provides 25 mg/mL phospholipids, 0.5 to 1.75 mg/mL triglycerides, 1.4 to 3.5 mg/mL free fatty acids, and <1.0 mg/mL total surfactant proteins. As an intratracheal suspension, it can be used for the prevention and treatment of neonatal respiratory distress syndrome. Survanta is manufactured by Abbvie.
Classification
Small molecule
Drug classpulmonary surfactants; tachykinin (neurokinin) receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID108778-82-1
RxCUI46967
ChEMBL IDCHEMBL1201624
ChEBI ID—
PubChem CID—
DrugBankDB06761
UNII ID—
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 687 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
288 adverse events reported
View more details